A study published Online First by The Lancet shows that by reducing dosing appropriately, it is possible for elderly patients-the group most affected by colorectal cancer (also known as bowel cancer)-to take part in randomised controlled clinical trials...
Ray Johnston's goal in three years is for his band to sell out at the 1,600-seat House of Blues in Dallas. In eight years, he wants to pack the 6,400-seat Verizon Theatre in Grand Prairie, and by 2030, to play to tens of thousands of fans at Cowboys Stadium in Arlington. Mr. Johnston's unmentioned goal, though, is to live another year after battling leukemia for the past seven...
AstraZeneca (NYSE:AZN) announced today encouraging results from a phase II study in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) who had received maintenance treatment with the investigational drug olaparib, after the completion of chemotherapy...
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Gemcitabine HCI for Injection, USP, in the 2 g dosage strength. APP will launch this presentation of Gemcitabine immediately. In January 2011, Teva Pharmaceuticals USA, Inc...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced final results from a randomized, multicenter, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC)...
GTx, Inc. (NASDAQ: GTXI) announced today in a Phase IIb clinical trial evaluating Ostarine™ (GTx-024), a selective androgen receptor modulator, for the treatment of muscle wasting in patients with cancer, Ostarine™ treatment improved physical function and overcame the negative prognostic effect of severe weight loss on overall survival in patients with non-small cell lung cancer...
Biothera Initiates Dosing In A Phase III Trial In Colorectal Cancer Patients
5/19/2011
Biothera began dosing patients today in a Phase III trial evaluating Imprime PGG® in combination with cetuximab (Erbitux®) as a potential new treatment for recurrent or progressive KRAS wild-type colorectal cancer. The trial design is built on data obtained in the company's previous clinical studies in colorectal cancer...
Children's Hospital Los Angeles Team Discovers Key To Fighting Drug-Resistant Leukemia
5/19/2011
Acute lymphoblastic leukemia, or ALL, is the most common form of childhood cancer. While most children treated for this disease survive, in a subgroup of patients the disease does not respond to treatment...
Recurring Cancers In Women With A History Of Breast Cancer Differ From The Original Tumors
5/19/2011
When women with a history of breast cancer learn they have breast cancer again, one of the first questions they and their doctors ask is: Has my cancer come back, or is this a new case? Now, new data from Fox Chase Cancer Center suggest that both new and recurring cancers will differ significantly from the original tumors, regardless of how many months or years women spent canc...
Link Between Lack Of Important 'Gatekeeper' Protein And Skin Cancer
5/19/2011
New research from North Carolina State University shows that a "gatekeeper" protein plays an important role in skin-cancer prevention in humans and lab mice. The protein, C/EBP alpha, is normally abundantly expressed to help protect skin cells from DNA damage when humans are exposed to sunlight...